November 8, 2007

News Release

For Immediate Release

THE JENEX CORPORATION ISSUES SHARES FOR DEBT

Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN, Frankfurt: JNX) announced today they have completed a transaction to issue 910,382 common shares at a deemed price of 15 cents per common share to extinguish a total $136,557.27 in trade payables. The TSX Venture Exchange approved this transaction.  The shares are subject to the customary four month hold period from date of issue.

About The Jenex Corporation

The Jenex Corporation owns a patented Thermal Therapy technology.  The first device developed from this technology is the Therapik® product, for relief of pain and itch caused by insect stings and bites.  Therapik® has been approved as a Class II medical device in Canada (TPD) and the United States (FDA), and has received CE approval in Europe.  The second device, interceptCS is the first product clinically proven and approved (TPD) to prevent cold sores.  interceptCS is available exclusively in Canada at Shoppers Drug Mart/Pharmaprix.  More information about the Corporation can be found at www.jenexcorp.com and www.interceptCS.com.

“Prevention is the Solution”

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility

for the accuracy or the contents of this press release.

Direct Inquiries to:

The Jenex Corporation

207  -  940 Sheldon Court

Burlington, Ontario L7L 5K6

Michael A. Jenkins

Telephone:  (905) 632-3830

Facsimile:  (905) 632-3774

Email:  jenex@jenexcorp.com

Website:  www.jenexcorp.com